Hansa Biopharma AB

As of June 30, 2026, Hansa Biopharma AB carries a market capitalization of 3.53B, placing it among publicly traded companies globally. Its enterprise value stands at 4.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hansa Biopharma AB's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Hansa Biopharma AB has 99.73M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 16.02, and the price-to-book ratio stands at -6.79.

These figures are as of June 30, 2026. The EV/Sales ratio of 19.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.01B versus a market cap of 3.53B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hansa Biopharma AB maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -198.72, indicating conservative leverage, while an interest coverage ratio of -2.73 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -92.21, reflecting losses generated across the asset base. The company generates approximately 1.63M in revenue per employee across its workforce of 127.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 14.52 indicates how many times Hansa Biopharma AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hansa Biopharma AB recorded 2.37M in income tax expense. The company reported a pretax loss of -816.50M and -818.87M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Hansa Biopharma AB's stock has gained approximately 14.46% over the past 52 weeks. The 50-day moving average sits at 38.62, while the 200-day moving average is 34.27.

Over the twelve months ended June 30, 2026, Hansa Biopharma AB generated 207.78M in revenue and converted that into -818.87M in net income, yielding earnings per share of -8.71. EBITDA reached -574.83M, while operating income came in at -596.00M.

As of June 30, 2026, Hansa Biopharma AB holds 552.81M in cash and equivalents against 1.03B in total debt, resulting in a net debt position of 474.49M. Total book value stands at -520.24M, with working capital of 136.55M providing operational flexibility.

Hansa Biopharma AB produced -532.21M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -532.21M - equivalent to -5.66 per share.

Over the twelve months ended June 30, 2026, Hansa Biopharma AB posted a gross margin of 62.09, reflecting its pricing power and cost economics. The operating margin of -286.84 and net profit margin of -394.11 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -15.99: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -27.59, meaning Hansa Biopharma AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Hansa Biopharma AB's most recent stock split took place on March 16, 2015 with a 964:1015 split ratio.